Young’s quest to improve drug safety spurred his entry to federal politics.
In 2009, a year after he was elected, he tabled a private member’s bill calling for an independent drug-monitoring agency with the power to order unsafe drugs off the market and issue plainly worded risk warnings.
before bed, I caught sight of a news post about Andy Murray. In addition, there is also a ball approved specifically for high altitude matches. For decades female tennis players have argued for equal pay.
He was said to have shouted at the umpire during his Miami Open match for having been handed – and then served with – a ball from the women’s game. I think I am correct in assuming that none of my readers have spent their Easter Weekend getting up to speed on the regulations for tennis balls. There are three main types of ball: Type 1 (for slower courts), Type 2 (standard) and Type 3 (for faster courts).
The result is an industry-regulator alliance primed to bring drugs to market.
Health Canada has an online database listing adverse reactions to drugs.
By law, doctors must report unfit drivers, and are paid to do so.
Fast-tracking drugs to market is like “air-traffic controllers being told to land planes more quickly,” he says.And he filed an individual suit against all three parties.The six-year battle, settled out of court, is chronicled in his book , published in 2009.But navigating it is next to impossible, and reporting adverse effects is voluntary for doctors and pharmacists.Even if a drug is found unsafe, the agency lacks the authority to unilaterally revise the label or remove it from market—or order a company to do so.More shocking to the former Ontario MPP, Health Canada knew of these risks: since approving Prepulsid in 1990, the agency, which approves and monitors prescription drugs through its Therapeutic Products Directorate, had sent four letters to doctors, the last in 1998, warning about serious adverse effects, including heart risks in children, women and infants. S., Young learned, Vanessa might not have been prescribed cisapride. In January 2000, two months before Vanessa died, the FDA issued an advisory alerting doctors of heart attack risks and rewrote label warnings; in April, it announced cisapride would be pulled from the market in July 2000.